Parkinson’s breakthrough: Researchers find way to halt disease progression
By
Alicia Lasek
Jun 07, 2019
Japanese researchers have successfully reduced Parkinson’s-like symptoms in mice. The breakthrough could unearth preventive treatments, they said.
First biosimilar approved by FDA to treat common eye degeneration in elders
By
Alicia Lasek
Sep 21, 2021
The Food and Drug Administration has approved a less expensive copy of the blockbuster drug Lucentis for treating age-related (wet) macular degeneration and several other eye conditions.
FDA OKs third antibody COVID therapy; variants spur new pause on another
By
Alicia Lasek
Jun 01, 2021
A new COVID-19 treatment made by GlaxoSmithKline now is the third monoclonal antibody therapy federally authorized to help prevent severe disease outcomes in high-risk patients. But gene variants are interfering...
HHS halts Eli Lilly’s single-drug COVID antibody treatment in U.S.; dual-drug alternative remains in...
By
Alicia Lasek
Mar 26, 2021
U.S. distribution of an infusion treatment using bamlanivimab only has been halted due to virus variant concerns, but an alternative antibody cocktail from the drugmaker can still be ordered, according...
Gout guidance highlights treat-to-target drug therapy
By
Alicia Lasek
May 12, 2020
Experts strongly recommend moving away from a fixed-dose approach to urate lowering therapy in updated guidelines for 2020.
Clinical briefs for Wednesday, Dec. 1
By
Alicia Lasek
Dec 01, 2021
Regeneron’s COVID-19 antibody drug may be less effective against omicron, drugmaker says … Pandemic taking toll on healthcare workers’ sleep patterns … Ambulance staffing shortage frustrating nursing...
Feds halt an Eli Lilly antibody therapy in 3 states due to variant fears, while boosting the treatment...
By
Alicia Lasek
Mar 19, 2021
A COVID-19 variant circulating widely in California, Arizona and Nevada has rendered bamlanivimab alone ineffective, an FDA official reports. But Lilly says an approved alternative treatment “maintains...
Alzheimer’s discoveries show new promise for drug development, expert says
By
Alicia Lasek
Jul 20, 2020
The discovery of new biomarkers — along with a focus on repurposed drugs — are optimistic signs for Alzheimer’s research, according to a five-year analysis.
High amyloid levels linked to early-stage Alzheimer’s
By
Alicia Lasek
Apr 06, 2020
Screening data from an Alzheimer’s drug trial suggests that higher brain amyloid levels exist well before clinical symptoms appear.
ADHD linked to Alzheimer’s disease across generations, scientists say
By
Alicia Lasek
Sep 14, 2021
Parents of children diagnosed with attention deficit hyperactivity disorder are more likely to receive a diagnosis of Alzheimer’s than their peers whose children do not have the condition, investigators...